Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.77 |
| ▸ | CNR1 | P21554 | 6/20 | 0.77 |
| ▸ | PPARA | Q07869 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388169 | 1.00 | CNR2 (0.77) | CNR2CNR1PPARA | |
| SCHEMBL12907719 | 0.95 | CNR2 (0.70) | CNR2CNR1PPARA | |
| SCHEMBL17565777 | 0.94 | CNR2 (0.69) | CNR2CNR1 | |
| Piperidine SCHEMBL6094702 | 0.90 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL6173947 | 0.89 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL4246366 | 0.89 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL276817 | 0.89 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL30571219 | 0.89 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL924033 | 0.89 | CNR2 (0.76) | CNR2CNR1PPARA | |
| Hydrochloric Acid SCHEMBL3002214 | 0.88 | CNR2 (0.74) | CNR2CNR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20230172874-A1 | USE OF CANNABIDIOL FOR THE TREATMENT OF INSOMNIA ASSOCIATED TO PAIN | GOBBI GABRIELLA (CA) | 2023-06-08 | — | — | US | disclosed |
| WO-2023089612-A1 | PERIPHERAL CB1 RECEPTOR ANTAGONISTS FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-05-25 | — | — | WO | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20190343822-A1 | TREATMENT FOR GLAUCOMA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-11-14 | — | — | US | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007035945-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006087732-A1 | AN AMORPHOUS AND THREE CRYSTALLINE FORMS OF RIMONABANT HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2006-08-24 | — | — | WO | disclosed |
| EP-1556373-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035566-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885PPARA 201/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | CNR2 4645/4885CNR1 4650/4885PPARA 3243/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | CNR2 4645/4885CNR1 4650/4885PPARA 3243/4885 |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR2 1/4885CNR1 2/4885PPARA 621/4885 |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | DHFR, DPYD, THPO | CNR2 933/4885CNR1 767/4885PPARA 1910/4885 |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CNR2 1/4885CNR1 2/4885PPARA 27/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR2 2/4885CNR1 1/4885PPARA 703/4885 |
| US-20220119365-A1 | CB1R RECEPTOR BLOCKERS WITH ACYCLIC BACKBONES | CNR1, CNR2, HCRTR1 | CNR2 2/4885CNR1 1/4885PPARA 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.